search
Back to results

Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

Primary Purpose

Prostate Cancer

Status
Unknown status
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
HDR brachytherapy monotherapy
Sponsored by
CSSS de Gatineau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prostate Cancer focused on measuring Brachytherapy, Monotherapy, HDR

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Biopsy proven Adenocarcinoma of the Prostate
  • Clinical stage T1c, T2a or T2b
  • PSA less than 20 ng/ml
  • Gleason Score 6 or 7

Exclusion Criteria:

  • Age less than 18 years
  • Clinical stage T2c, T3 ou T4
  • Clinical Stage N1
  • Clinical Stage M1
  • Prostate Specific Antigen (PSA) more than 20 ng/ml
  • Gleason score 8 or higher
  • IPSS score 19 or higher with alpha-blockers
  • Past radiation therapy to the pelvis
  • History of Collagen Vascular Disease
  • History of Inflammatory Bowel Disease
  • Bilateral Hip Prosthesis

Sites / Locations

  • CSSS de Gatineau

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HDR brachytherapy monotherapy

Arm Description

Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.

Outcomes

Primary Outcome Measures

Disease-free survival
Disease free survival as evaluated by absence of biochemical recurrence (Phoenix criteria) and absence of clinically/radiologically diagnosed local, regional or distant recurrence.

Secondary Outcome Measures

Genito-urinary (GU) toxicity
Toxicity according to International prostate symptom score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires.

Full Information

First Posted
February 23, 2014
Last Updated
January 30, 2021
Sponsor
CSSS de Gatineau
search

1. Study Identification

Unique Protocol Identification Number
NCT02077335
Brief Title
Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer
Official Title
Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 2014 (undefined)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
September 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
CSSS de Gatineau

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
Brachytherapy, Monotherapy, HDR

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HDR brachytherapy monotherapy
Arm Type
Experimental
Arm Description
Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
Intervention Type
Radiation
Intervention Name(s)
HDR brachytherapy monotherapy
Intervention Description
Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following: Prostate : V100 > 95% V150 30-35% V200 < 15% D90 > 90% (12,15Gy) Bladder • V75 < 1cc Rectum • V75 < 1cc Urethra V125 = 0cc D10 < 120% Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure.
Primary Outcome Measure Information:
Title
Disease-free survival
Description
Disease free survival as evaluated by absence of biochemical recurrence (Phoenix criteria) and absence of clinically/radiologically diagnosed local, regional or distant recurrence.
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Genito-urinary (GU) toxicity
Description
Toxicity according to International prostate symptom score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires.
Time Frame
6 weeks, 2 years and 5 years post treatment
Other Pre-specified Outcome Measures:
Title
Overall survival
Time Frame
5 years
Title
Gastro-Intestinal (GI) Toxicity
Description
Toxicity according to Expanded Prostate Index Composite (EPIC) questionnaires.
Time Frame
6 weeks, 2 years and 5 years post treatment

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Biopsy proven Adenocarcinoma of the Prostate Clinical stage T1c, T2a or T2b PSA less than 20 ng/ml Gleason Score 6 or 7 Exclusion Criteria: Age less than 18 years Clinical stage T2c, T3 ou T4 Clinical Stage N1 Clinical Stage M1 Prostate Specific Antigen (PSA) more than 20 ng/ml Gleason score 8 or higher IPSS score 19 or higher with alpha-blockers Past radiation therapy to the pelvis History of Collagen Vascular Disease History of Inflammatory Bowel Disease Bilateral Hip Prosthesis
Facility Information:
Facility Name
CSSS de Gatineau
City
Gatineau
State/Province
Quebec
ZIP/Postal Code
J8P 7H2
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer

We'll reach out to this number within 24 hrs